Research Analysts Issue Forecasts for AQST FY2027 Earnings

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Stock analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Aquestive Therapeutics in a research report issued on Monday, March 9th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.52) per share for the year. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

Several other research firms have also weighed in on AQST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $8.80.

Aquestive Therapeutics Price Performance

Shares of NASDAQ:AQST opened at $4.29 on Tuesday. The business has a 50-day moving average of $4.17 and a two-hundred day moving average of $5.22. The firm has a market capitalization of $523.55 million, a PE ratio of -5.50 and a beta of 1.61. Aquestive Therapeutics has a 12 month low of $2.12 and a 12 month high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 4th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The company had revenue of $13.02 million during the quarter, compared to analysts’ expectations of $13.28 million.

Institutional Investors Weigh In On Aquestive Therapeutics

Large investors have recently modified their holdings of the stock. Invesco Ltd. raised its holdings in shares of Aquestive Therapeutics by 20.2% during the 4th quarter. Invesco Ltd. now owns 64,993 shares of the company’s stock valued at $420,000 after buying an additional 10,920 shares during the period. Voloridge Investment Management LLC purchased a new position in Aquestive Therapeutics in the 4th quarter worth approximately $1,254,000. Numerai GP LLC purchased a new position in Aquestive Therapeutics in the 4th quarter worth approximately $789,000. Occudo Quantitative Strategies LP acquired a new stake in Aquestive Therapeutics in the fourth quarter valued at approximately $365,000. Finally, Millennium Management LLC grew its position in Aquestive Therapeutics by 19.1% in the fourth quarter. Millennium Management LLC now owns 1,535,369 shares of the company’s stock valued at $9,918,000 after acquiring an additional 246,040 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.